Effectiveness of Third-Class Biologic Treatment in Crohn’s Disease: A Multi-Center Retrospective Cohort Study

Ahmad Albshesh 1,*, Joshua Taylor 2, Edoardo V. Savarino 3, Marie Truyen 4, Alessandro Armuzzi 5, Davide R. Ribaldone 6, Ariella Bar-Gil Shitrit 7, Morine Fibelman 8, Paulina Molander 9, Claire Liefferinckx 10, Stephane Nancey 11,12, Mohamed Korani 13,14, Mariann Rutka 15, Manuel Barreiro-de Acosta 16, Viktor Domislovic 17, Gerard Suris 18, Carl Eriksson 19, Catarina Alves 20, Afroditi Mpitouli 21, Caroline di Jiang 22, Katja Tepes 23, Marina Coletta 24, Kalliopi Foteinogiannopoulou 25, Javier P. Gisbert 26, Hadar Amir-Barak 27, Mohamed Attaubi 28, Jakob Seidelin 29, Waqqas Afif 2, Carla Marinelli 3, Triana Lobaton 4, Daniela Pugliese 5, Nitsan Maharshak 8, Anneline Cremer 10, Jimmy K. Limdi 13,14, Tamás Molnár 15, Borja Otero-Alvarin 16, Zeljko Krznaric 17, Fernando Magro 20, Konstantinos Karmiris 21, Tim Raine 22, David Drobne 23, Ioannis Koutoubakis 25, Maria Chaparro 26, Henit Yanai 27, Johan Burisch 28 and Uri Kopylov 1

1 Sheba Medical Center, Tel Hashomer, Israel, Department of Gastroenterology, Sackler School of Medicine, Tel-Aviv University, Tel-Aviv 52621, Israel; ukopylov@gmail.com
2 Department of Gastroenterology, Montreal General Hospital, Montreal, QC T6G 1Z9, Canada; joshua.taylor@mail.mcgill.ca (J.T.); waqqas.afif@mail.mcgill.ca (W.A.)
3 Division of Gastroenterology, Department of Surgery, Oncology and Gastroenterology, University of Padua, 35128 Padua, Italy; edoardsosavarino@gmail.com (E.V.S.); carla.marinelli88@gmail.com (C.M.)
4 IBD Unit, Department of Gastroenterology, Ghent University Hospital, 9000 Ghent, Belgium; Marie.Truyen@uzgent.be (M.T.); Triana.Lobaton@orthopaedie.ugent.be (T.L.)
5 IBD Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, 00168 Rome, Italy; alearmuzzi@yahoo.com (A.A.); danielapugliese@gmail.com (D.P.)
6 Division of Gastroenterology, Department of Medical Sciences, University of Turin, 10126 Turin, Italy; davrib_1998@yahoo.com
7 Shaare Zedek Medical Center, Faculty of Medicine, Digestive Diseases Institute, Hebrew University of Jerusalem, Jerusalem 9372212, Israel; ariellash@szmce.org.il
8 Tel Aviv Medical Center, Department of Gastroenterology and Liver Diseases, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv 643900, Israel; morin.fe@gmail.com (M.F.); nitsam@tlvmc.gov.il (N.M.)
9 Abdominal Center, Department of Gastroenterology, Helsinki University Hospital, 00101 Helsinki, Finland; pauliina.molander@hus.fi
10 Department of Gastroenterology, Erasme University Hospital, 1070 Brussels, Belgium; claire2301@gmail.com (C.L.); anneline.cremer@erasme.ulb.ac.be (A.C.)
11 Department of Gastroenterology, Hospices Civils de Lyon, University Claude Bernard Lyon, 69495 Lyon, France; stephane.nancey@chu-lyon.fr
12 INSERM, U1111, CIRIL, 69007 Lyon, France
13 Division of Gastroenterology, The Penaccine Acute Hospitals NHS Trust, Manchester M8 6RB, UK; Mohamed.Korani@pat.nhs.uk (M.K.); jimmy.limdi@nhs.net (J.K.L.)
14 Manchester Academic Health Sciences University, University of Manchester, Manchester BL9 7TD, UK
15 First Department of Medicine, University of Szeged, H-6720 Szeged, Hungary; mariannrutka@gmail.com (M.R.); molnar.tamas@med.u-szeged.hu (T.M.)
16 IBD Unit, Gastroenterology Department, University Hospital of Santiago de Compostela, 15706 Santiago, Spain; manubardeiro@hotmail.com (M.B.d.A.); borja.alvarin@gmail.com (B.O.-A.)
17 Department of Gastroenterology, Hepatology, and Nutrition, University Hospital Centre Zagreb, 10000 Zagreb, Croatia; viktor.domislovic@gmail.com (V.D.); zeljko.krznaric1@zg-t.com.hr (Z.K.)
18 Digestive System Service, Bellvitge University Hospital, Catalan Institute of Health, 08907 Barcelona, Spain; tsuris@bellvitgehospital.cat
19 Department of Gastroenterology, Faculty of Medicine and Health, Örebro University, SE-70182 Örebro, Sweden; carl.erksson@regionorebro.se
20 Department of Gastroenterology, Centro Hospitalar São João, 4200319 Porto, Portugal; catarina1ves_04@hotmail.com (C.A.); fernandomagro65@gmail.com (F.M.)
21 Department of Gastroenterology, Venizeleion General Hospital, Heraklion, 71409 Crete, Greece; bitouliafro@hotmail.com (A.M.); kkarmiris@gmail.com (K.K.)
22 Department of Gastroenterology, Addenbrooke’s Hospital, Cambridge University Hospitals, Cambridge CB2 0QQ, UK; caroline.di.jiang@gmail.com (C.d.J.); tim.raine@addenbrookes.nhs.uk (T.R.)
Abstract: Background: Multiple studies have described the effectiveness of ustekinumab (UST) and vedolizumab (VDZ) in patients with Crohn’s disease (CD) failing anti-Tumor necrosis factors (TNFs); however, the effectiveness of VDZ or UST as a third-class biologic has not yet been described. Aims and Methods: In this retrospective multicenter cohort study, we aimed to investigate the effectiveness of VDZ and UST as a third-class biologic in patients with CD. Results: Two-hundred and four patients were included; 156/204 (76%) patients received VDZ as a second- and UST as a third-class therapy (group A); the remaining 48/204 (24%) patients received UST as a second- and VDZ as a third-class therapy (group B). At week 16–22, 87/156 (55.5%) patients and 27/48 (56.2%) in groups A and B, respectively, responded to treatment (p = 0.9); 41/156 (26.2%) and 15/48 (31.2%) were in clinical remission (p = 0.5). At week 52; 89/103 (86%) patients and 25/29 (86.2%) of the patients with available data had responded to third-class treatment in groups A and B, respectively (p = 0.9); 31/103 (30%) and 47/29 (24.1%) were in clinical remission (p = 0.5). Conclusion: Third-class biological therapy was effective in more than half of the patients with CD. No differences in effectiveness were detected between the use of VDZ and UST as a third-class agent.

Keywords: Crohn’s disease; anti-TNF failure; treatment response; treatment failure; ustekinumab; vedolizumab

1. Introduction

In recent years, our arsenal of therapeutic options in Crohn’s disease (CD) has been expanding. Despite the diversity of therapeutic options, loss of response remains a significant challenge across all therapeutic agents [1,2]. Tumor necrosis factor (TNF)-alpha inhibitors are the most frequently used first-class biologics; however, approximately 30% of patients experience primary and at least 13% experience secondary loss of response per year [3,4]. Both ustekinumab (UST) and vedolizumab (VDZ) are frequently used as second-class options, with response rates of 40–70% and loss of response rates approximating 20–30% within the first year [5–26]. As we are currently lacking knowledge regarding predictors of the response to either of these biologic classes of treatment [7], the decision is largely empirical.

Recently, two real-world studies compared the effectiveness of VDZ and UST in CD patients following loss of response to anti-TNFs [27,28]. In both studies, UST was superior to VDZ. However, loss of response to a subsequent second-class biologic is frequent. Moreover, the number of previously utilized biologics is associated with a diminished
likelihood of response to biological therapy [29]. To date, there is scarce evidence regarding the effectiveness of a third-class biologic after the failure of two previous classes in CD [30].

The current study aimed to evaluate the likelihood and potential predictors of response to a third-class biologic in CD patients with a previous failure of two biologic classes.

2. Materials and Methods

2.1. Patient Population

This was a multicenter retrospective cohort study. We included adult patients with an established CD diagnosis who received three different biologic classes for disease treatment. We included all patients who received at least one dose of the third-class biologic. Only patients with active disease (defined as Harvey–Bradshaw index (HBI) ≥ 5) were included. Patients with ostomy or pouch surgery were excluded. Patients that had not yet reached the primary endpoint (week 16) while on active third-class therapy were also excluded.

The study was approved by the Sheba Medical Center ethics committee and written, informed consent was obtained from each patient included in the study. Approval was granted for Helsinki protocol SMC-5598-08 on 28 January 2009. The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki, as reflected in a priori approval by the institution’s human research committee.

2.2. Clinical Scores and Outcomes

The primary outcome of the study was clinical response at week 16–22 (defined by a reduction of HBI ≥ 3). Secondary outcomes included clinical remission (HBI ≤ 4) at week 16–22, clinical remission and response in week 52, steroid-free clinical remission at week 16–22, C-Reactive Protein (CRP) normalization (CRP serum concentration levels less than normal range as per the cut-off used in the corresponding institutions).

2.3. Statistical Methods

Continuous variables were articulated as the median and interquartile range (IQR). Categorical variables were analyzed using Chi-squared/Fisher’s exact tests and continuous variables by the t-test/Mann–Whitney test as appropriate. A p-value < 0.05 was considered statistically significant. We constructed a multivariate logistic regression model to identify the independent predictors of week 16–22 response and remission, as well as treatment continuation after induction. Variables with a significance level <0.1 based on univariate analysis were included in the multivariate model. To investigate the effect of the variables on treatment discontinuation, we planned a survival analysis using a Kaplan Meyer survival curve or Cox proportional hazard analysis as appropriate. The analysis was performed using IBM SPSS (version 22.0; Armonk, NY, USA).

3. Results

3.1. Baseline Characteristics

Two-hundred and four patients from 27 centers in 15 countries (22 Europe, 4 Israel, and 1 Canada) were included in the study. Baseline characteristics are detailed in Table 1. All patients had received anti-TNFs as a first-class biological therapy (51 patients had previously received one, 130 had received two, and 23 had received three anti-TNFs). One hundred and fifty-six out of 204 (76%) patients received VDZ as a second-class therapy (median treatment duration on VDZ was 12 months (IQR 5–20)) and UST as a third-class therapy (group A); the remaining 48 of 204 (24%) patients received UST as a second-class therapy (median treatment duration on UST was 10 months (IQR 6.5–18)) and VDZ as a third-class therapy (group B).
Table 1. Patients’ demographic and clinical characteristics.

|                          | Total     | Group A          | Group B          | p-Value  |
|--------------------------|-----------|------------------|------------------|----------|
| n (%)                    | 204       | 156 (76.4%)      | 48 (23.6%)       | p < 0.01 * |
| Age at start of 3rd-class biological therapy, years, median (IQR) | 41.5 (32–53) | 43.6 (32–52.7)  | 43.5 (31–54.7)  | p = 0.96  |
| Gender—male, n (%)       | 96 (47.05%)| 74 (47.4%)       | 22 (45.8%)       | p = 0.84  |
| Current smoker, n (%)    | 36 (17.6%)| 23 (15.7%)       | 9 (18.7%)        | p = 0.08  |
| Age at diagnosis, years median (IQR) | 23 (17–32) | 24 (18–34)       | 20 (15–31.7)     | p = 0.13  |
| Disease duration, years, median (IQR) | 16 (10.25–22) | 15 (10–20.7)     | 16.5 (11–25.75)  | p = 0.13  |

Location (n, %)

|                        | Total       | Group A                | Group B                | p-Value  |
|------------------------|-------------|------------------------|------------------------|----------|
| Ileum                  | 55 (26.9%)  | 42 (26.9%)             | 13 (27%)               | p = 0.98  |
| Colon                  | 41 (20.09%) | 36 (23.%)              | 5 (10.1%)              | p = 0.06  |
| Ileocolonic            | 107 (52.45%)| 78 (50%)               | 29 (60.4%)             | p = 0.20  |
| UGI                    | 1 (0.49%)   | 0 (0%)                 | 1 (2%)                 | p = 0.16  |

Behavior (n, %)

|                           | Total       | Group A                | Group B                | p-Value  |
|---------------------------|-------------|------------------------|------------------------|----------|
| Nonstricturing nonpenetrating | 70 (43.31%) | 55 (35.2%)             | 15 (31.2%)             | p = 0.60  |
| Stricturing               | 55 (26.96%) | 46 (29.4%)             | 9 (18.7%)              | p = 0.14  |
| Penetrating               | 64 (31.7%)  | 48 (30.7%)             | 16 (33.3%)             | p = 0.73  |
| Peri-anal disease, n (%)  | 85 (41.66%) | 59 (37.8%)             | 26 (54.1%)             | p = 0.04 * |

Prior anti-TNF therapy exposure, n (%)

|                        | Total       | Group A                | Group B                | p-Value  |
|------------------------|-------------|------------------------|------------------------|----------|
| One previous anti-TNF treatment | 51 (25%)   | 42 (26.9%)             | 9 (18.7%)              | p = 0.25  |
| Two previous anti-TNF treatments | 130 (63.72%) | 100 (64.1%)         | 30 (62.5%)             | p = 0.84  |
| Three previous anti-TNF treatments | 23 (11.27%) | 14 (8.9%)           | 9 (18.7%)              | p = 0.06  |

Disease activity

|                        | Total       | Group A                | Group B                | p-Value  |
|------------------------|-------------|------------------------|------------------------|----------|
| Harvey Bradshaw Index, Median (IQR) | 8 (7–12)   | 8 (7–11)               | 9 (6–12)               | p = 0.24  |
| Elevated CRP, n (%)    | 132 (64.7%) | 101 (64.7%)            | 31 (64.5%)             | p = 0.98  |
| Fecal calprotectin > 250 µg/g, n (%) | 73 (35.78%) | 52 (33.3%)             | 16 (33.3%)             | p = 1.00  |

Concomitant medications, n (%)

|                        | Total       | Group A                | Group B                | p-Value  |
|------------------------|-------------|------------------------|------------------------|----------|
| Corticosteroids        | 80 (39.21%) | 62 (39.7%)             | 18 (37.5%)             | p = 0.78  |
| Immunosuppressant      | 50 (24.5%)  | 37 (23.7%)             | 13 (27%)               | p = 0.63  |
| Both corticosteroids and immunosuppressant | 18 (8.82%) | 12 (7.69%)             | 6 (12%)                | p = 0.30  |

Abbreviations: n, number; IQR, interquartile range; UGI, upper gastrointestinal; anti-TNF, anti-tumor necrosis factor; CRP, C-reactive protein; *, significant p-value; Group A = ustekinumab, Group B = vedolizumab.

Median disease duration before the start of third-class treatment was 16 years (IQR 10–22). All patients had active CD (median HBI: 8 (IQR 7–12)) at the time of third-class onset.

One-hundred and thirty-two (64.7%) had elevated CRP at treatment onset. The patient characteristics were similar between the groups, with the exception of the prevalence of perianal disease (group A: 37.8% vs group B: 54.1%, p = 0.04). Figure 1 describes the patient flow during the study.
Figure 1. Chart of the patients’ flow during the study period. CD, Crohn’s disease; group A, patients received vedolizumab (VZD) as a second-class therapy and ustekinumab (UST) as a third-class therapy; group B, patients received UST as a second-class therapy and VDZ as a third-class therapy.

3.2. Treatment Outcomes

3.2.1. Induction Period (Weeks 16–22)

The overall response rate at week 16–22 was 55.8% (87/156 (55.5%) and 27/48 (56.2%) in groups A and B, respectively (p = 0.9)). Clinical remission was achieved by 56/204 (27.4%) patients (41/156 (26.2%) and 15/48 (31.2%), (p = 0.5)) (Figure 2A). CRP normalized in 76/172 (44.18%) patients with CRP values available at this time point (59/134 (44.02%) and 17/38 (44.7%), (p = 0.9)) (Figure 2B). Systemic corticosteroids were discontinued in 51/80 (63.7%) patients who were on corticosteroids at the treatment onset. Corticosteroid-free remission was achieved by 18/80 (22.4%) (14/62 (22.5%) and 4/18 (22.2%), (p = 0.9)) (Figure 2B).

Figure 2. Outcome. (A): The proportion of patients achieving clinical remission (HBI ≤ 4) and clinical response (delta HBI ≥ 3) during the study period. (B): The proportion of patients achieving corticosteroid-free clinical remission during the study period, and the proportion of patients with CRP normalization (CRP serum concentration levels less than normal range as per cut-off used in the corresponding institutions). CRP, C-reactive protein, HBI: Harvey–Bradshaw index.
There was a significant negative association between elevated CRP and clinical response ($p = 0.02$). Clinical remission was negatively associated with elevated CRP and smoking ($p = 0.03$ and $p = 0.01$, respectively) (Table 2).

### Table 2. Clinical variables associated with clinical response, remission, and treatment discontinuation.

|                      | $p$-Value for Clinical Response (Week 16–22) | $p$-Value for Clinical Remission (Week 16–22) | $p$-Value for Treatment Discontinuation Univariate | OR for Treatment Discontinuation |
|----------------------|--------------------------------------------|---------------------------------------------|--------------------------------------------------|----------------------------------|
| Group                | 0.95                                       | 0.5                                         | 0.8                                             | OR, 0.9; 95% CI, 0.4–2.5         |
| Gender               | 0.33                                       | 0.63                                        | 0.08                                            | OR, 1.5; 95% CI, 0.3–1.3         |
| Age at start of 3rd-class biological therapy | 0.97                                       | 0.74                                        | 0.6                                             | OR, 0.98; 95% CI, 0.9–1          |
| Age at diagnosis     | 0.94                                       | 0.73                                        | 0.1                                             | OR, 1.11; 95% CI, 0.9–1          |
| Disease duration at 3rd-class onset              | 0.74                                       | 0.4                                         | 0.01 *                                          | OR, 0.93; 95% CI, 1–1.1          |
| Current smoker       | 0.84                                       | 0.01 *                                      | 0.09                                            | OR, 1.8; 95% CI, 0.1–2           |
| Location             | 0.11                                       |                                              | 0.6                                             | OR, 0.8; 95% CI, 0.5–3           |
| Behavior             | 0.25                                       | 0.34                                        | <0.01 *                                         | OR, 2.1; 95% CI, 0.1–1           |
| Prior anti-TNF therapy exposure                   | 0.08                                       | 0.06                                        | 0.6                                             | OR, 1.2; 95% CI, 0.4–1.5         |
| Elevated CRP         | 0.02 *                                     | 0.03 *                                      | 0.2                                             | OR, 0.5; 95% CI, 0.7–5           |
| Corticosteroids      | 0.23                                       | 0.34                                        | 0.2                                             | OR, 1.7; 95% CI, 0.2–1.2         |
| Concomitant immunomodulators | 0.14                                      | 0.29                                        | <0.01 *                                         | OR, 0.04; 95% CI, 0.01–0.18      |

Abbreviations: $n$, number; IQR, interquartile range; OR, odds ratio; UGI, upper gastrointestinal; anti-TNF, anti-tumor necrosis factor; CRP, C-reactive protein; *, significant $p$-value; Group A = ustekinumab, Group B = vedolizumab.

3.2.2. Maintenance (Week 52)

One hundred and thirty-two patients had data available for analysis for week 52 (103/132 in group A and 29/132 in group B) (Figure 1). The overall response rate was 87.1% (89/103 (86.4%) and 25/29 (86.2%) in groups A and B, respectively ($p = 0.9$)). Clinical remission was achieved by 38/132 (28.7%) patients (31/103 (30%) and 7/29 (24.1%), ($p = 0.5$)) (Figure 2A). CRP normalized in 52/101 (51.4%) patients with CRP values available at this time point (42/80 (51.2%) and 10/21 (47.6%), ($p = 0.6$)) (Figure 2B). Systemic corticosteroids were discontinued in 34/45 (75.5%) patients who were on corticosteroids at the time of third-class agent initiation. Corticosteroid-free remission was achieved by 12/45 (26.6%) patients ($p = 0.2$) (Figure 2B).

Seventy-two patients had no data available for analysis in week 52 (53/156 in group A and 19/48 in group B). The last follow-up in these patients was with a median of 21 weeks (IQR 17–38). The overall response rate was 52.7% (28/53 (52.8%) and 10/19 (52.6%) in groups A and B, respectively ($p = 0.4$)). Clinical remission was achieved by 18/72 (25%) patients (14/53 (26.4%) and 4/19 (21%), ($p = 0.3$)). CRP normalized in 12/46 (26%) patients with CRP values available at this time point (10/33 (30.3%) and 2/13 (15.3%), ($p = 0.1$)). Systemic corticosteroids were discontinued in 17/30 (56.6%) patients who were on corticosteroids at the time of third-class agent initiation. Corticosteroid-free remission was achieved by 8/30 (26.6%) patients ($p = 0.2$) (Figure 2B).

Dose escalation was required in 104/204 (50.9%) patients (74/156 (47.4%) in group A with a median time of 26 weeks (IQR 8–52) and 30/48 (62.5%) in group B with a median time of 26 weeks (IQR 15–50), respectively ($p = 0.03$); sixty-nine out of them (66.3%) achieved clinical remission or response by the end of the follow-up (39/74 (52.7%) and 30/48 (62.5%), respectively, ($p = 0.14$)).
3.2.3. Treatment Discontinuation

Seven patients stopped the treatment before week 16, with a median of 10 weeks (IQR 8–12), mainly due to a primary non-response. The overall treatment discontinuation was observed in 19.11% of the patients (36/204), with a median follow-up duration of 48 (IQR 21–52) weeks. Twenty-seven patients out of 156 (17.3%) in group A with a median time of 21 weeks (IQR 16–20) and 9/48 (18.75%) in group B with a median time of 36 weeks (20–45) discontinued treatment (hazard ratio, 1.01; 95% confidence interval (CI), 0.49–2, \( p = 0.9 \)). The Kaplan–Meier curve for discontinuation-free survival is presented in Figure 3.

![Kaplan-Meier Survival by group](#)

**Figure 3.** Kaplan–Meier curve of treatment discontinuation-free analysis. Abbreviations: Group A, patients receiving vedolizumab (VZD) as a second-class therapy and ustekinumab (UST) as a third-class therapy; Group B, patients receiving UST as a second-class therapy and VDZ as a third-class therapy.

The main reason for the discontinuation of both treatment groups was a lack of response (group A: 85%, group B: 77.7%). The rest discontinued the treatment because of: patient decision (\( n = 2 \)), adverse event (3), active extraintestinal manifestation (1).

On univariable analysis, treatment continuation was negatively associated with disease duration at third-class agent onset, and stricturing disease behavior (\( p = 0.008 \), odds ratio (OR) 0.93; 95% CI 1–1.1), \( p = 0.004 \) (OR 2.1; 95% CI 0.1–1.1), respectively); and positively associated with immunomodulatory drug use (\( p = 0.001 \), OR 0.04; 95% CI 0.01–0.18). However, on multivariate analysis, only concomitant use of immunomodulatory drug use was positively associated (relative risk (RR) 0.014, 95% confidence interval (CI) 0.001–0.31) and disease duration at third-class agent onset was negatively associated with treatment continuation (Table 2).

3.2.4. Safety

Adverse events during the follow-up occurred in 19/204 (9.31%) patients. Thirty patients out of the 204 (14.7%) were hospitalized; the reasons for hospitalization are detailed in Table 3. Twenty-seven patients out of the 204 (13.2%) required surgical intervention, as detailed in Table 3.
Table 3. Adverse events, hospitalization, and surgeries during the follow-up period in each group.

| Adverse event                                      | Group A | Group B |
|---------------------------------------------------|---------|---------|
| Arthralgia                                         | 4       | 2       |
| Skin reaction d/t infusion                         | -       | 1       |
| Recurrent infection                                | 4       | -       |
| Psoriasis                                         | 1       | 1       |
| Depression                                        | 2       | -       |
| Severe anemia                                      | -       | 1       |
| Dermatitis/eczema                                  | -       | 1       |
| Occlusion due to stenosis with surgery             | 1       | -       |
| New heart failure                                  | 1       | -       |

| Hospitalization                                    |         |         |
|---------------------------------------------------|---------|---------|
| Flare                                             | 10      | 10      |
| SBO                                               | 2       | -       |
| Perianal abscess                                   | 1       | 1       |
| Depression                                        | 1       | 1       |
| Enterocutaneous fistula                            | 1       | 1       |
| Acute appendicitis                                 | 1       | -       |
| Diverticulitis                                     | -       | 1       |

| Surgery                                           |         |         |
|---------------------------------------------------|---------|---------|
| Small bowel resection                              | 3 *     | 2       |
| Perianal abscess                                   | -       | 3       |
| Rt. colectomy                                      | 1       | -       |
| Total colectomy                                    | 1       | -       |
| Ileocolonic resection                              | 8       | 3       |
| Fistulotomy                                        | 1       | 2       |
| Rectal cancer resection                            | -       | 1       |
| Colostomy                                          | 1       | -       |
| Rectal surgery                                     | 1       | -       |

Abbreviations: SBO, small bowel obstruction; *, combined with fistulotomy.

4. Discussion

Our study demonstrates that third-class biologic therapy is a feasible, effective, and safe option in Crohn’s disease. It is well established that the number of prior treatments is negatively associated with therapeutic success \[29,31,32\], and that biologic-naïve patients have a substantially higher likelihood of a response to treatment in inflammatory bowel diseases (IBDs) \[17,33–37\]. Until a few years ago, our therapeutic armamentarium in IBD was limited to TNF-alpha inhibitors only, but since then it has expanded to include anti-integrins, IL12/23 blockers, and JAK inhibitors. The natural history of utilization of any new drug naturally favors its use in patients who failed previous and better established treatments: thus, early real-world experience (RWE) series with VDZ included few biologic-naïve patients \[18,21,26,38\], whereas later series addressing biologic-naïve patients demonstrated higher effectiveness in comparison to those early publications \[17,39,40\]; for UST, data for biologic-naïve patients is still sparse. Similarly, the literature regarding the use of third-class biologics in IBD is limited to small numbers of patients in RWE series of biologic-experienced patients \[27,41–43\]. To date, the personalization of therapeutic decisions in IBD is underdeveloped, with limited clues to suggest which succession of therapeutic regimens is superior and subsequently likely to work best in patients failing several consecutive biologic treatments.

Our study focused on the effectiveness and safety of a third-class biologic in patients who had failed two previous classes of biologics. The overall effectiveness of the third-class agent was quite comparable to previous RWE reports on UST and VDZ \[15,44\]. In several previous studies, UST appeared to be more effective than VDZ in CD patients.
refractory to anti-TNFs. However, these studies included UST or VDZ as second-class agents and not as third-class agents [27,28].

Adverse events were rare and in line with the previous reports as well. In our study, concomitant immunomodulatory therapy was not associated with the likelihood of response or remission, in similarity with the recently published data [45,46]; nonetheless, the risk of treatment discontinuation was higher in patients on monotherapy. The effect of concomitant immunomodulators in the present study could be explained by a decrease in the risk of anti-drug antibody formation in line with the recently reported data on sequential anti-TNF use [47] or due to an additional anti-inflammatory effect [48,49]. Another somewhat surprising finding was the lack of association of the number of previously used anti-TNFs with therapeutic outcomes. A possible explanation for this observation could stem from the fact that all our patients have already experienced failure of multiple biologics, potentially obviating the subtle differences that could have been observed in a more treatment-naïve cohort.

Despite the fact that 19.11% of the patients discontinued the therapy, the majority continued the therapy with a high response (87.1%) and remission rate (28.7%). Importantly, as the patients included in this cohort have already experienced multiple classes of biological therapy and have quite exhausted their treatment options, it is plausible that in a proportion of cases the treatment was continued for a longer duration of time despite the lack of a clear early therapeutic response.

Unfortunately, the groups (VDZ or UST as a third-class agent) were dissimilar in size; the likely explanation for this is the earlier introduction of VDZ into clinical practice. Although we could not demonstrate any significant difference between the groups in either clinical characteristics or outcomes, the comparison is compromised by the disproportional cohort size. Some of the additional limitations of our study are inherent to an RWE multicenter retrospective study design (including a small number of patients with available endoscopic data; missing laboratory data, including drug levels and anti-drug antibodies; and heterogeneity in the scheduled visit dates, follow up data about perianal disease, and extraintestinal manifestations). Therefore, no conclusion could be drawn on the effect of these third-class biologicals on endoscopic endpoints and perianal disease. The study cohort was narrow in terms of age (41.5 years old (IQR 32–53)) and may not well reflect the responses of all patients. There is no representation for the elderly nor the young under the age of 30.

Despite the aforementioned limitations, our study supports the use of third-class biologics in CD. Further research is required to identify the most effective succession of treatment regimens in IBD, and to further personalize decision-making on those challenging patients.

**Author Contributions:** Conceptualization, A.A. (Ahmad Albshesh) and U.K.; data curation, A.A. (Ahmad Albshesh), J.T., E.V.S., M.T., A.A. (Alessandro Armuzzi), D.G.R., A.B.-G.S., M.F., P.M., C.L., S.N., M.K., M.R., M.B.-d.A., V.D., G.S., C.E., C.A., A.M., C.d.J., K.T., M.C. (Marina Coletta), K.F., J.P.G., H.A.-B., M.A., J.S., W.A., C.M., T.L., D.P., N.M., A.C., J.K.L., T.M., B.O.-A., Z.K., F.M., K.K., T.R., D.D., I.K., H.V., M.C. (Maria Chaparro), J.B. and U.K.; formal analysis, A.A. (Ahmad Albshesh); Methodology, A.A. (Ahmad Albshesh) and U.K.; project administration, A.A. (Ahmad Albshesh); resources, A.A. (Ahmad Albshesh); validation, U.K.; writing—original draft, A.A. (Ahmad Albshesh); writing—review and editing, J.T., E.V.S., M.T., A.A. (Alessandro Armuzzi), D.G.R., A.B.-G.S., M.F., P.M., C.L., S.N., M.K., M.R., M.B.-d.A., V.D., G.S., C.E., C.A., A.M., C.d.J., K.T., M.C. (Marina Coletta), K.F., J.P.G., H.A.-B., M.A., J.S., W.A., C.M., T.L., D.P., N.M., A.C., J.K.L., T.M., B.O.-A., Z.K., F.M., K.K., T.R., D.D., I.K., H.V., M.C. (Maria Chaparro), J.B. and U.K. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research received no funding.

**Institutional Review Board Statement:** The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Sheba Medical Center ethics committee (protocol code SMC-5598-08 on 28 January 2009).
Informed Consent Statement: Informed consent was obtained from each patient included in the study. Approval was granted for Helsinki protocol SMC-5598-08 on 28 January 2009. The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a priori approval by the institution’s human research committee.

Data Availability Statement: No new data were created or analyzed in this study. Data sharing is not applicable to this article.

Conflicts of Interest: Ahmad Albshesh: received speaking fees from Takeda; Joshua Taylor: none; Edorado V. Savarino: received lecture or consultancy fees from Medtronic, Reckitt Benckiser, Takeda, Merck & Co, Bristol-Myers Squibb, Abbvie, Amgen, Novartis, Fresenius Kabi, Sandoz, Sofar, Malesci, Janssen, Gelifols, Aurora Pharma, Innovamedica, Johnson & Johnson, SILA, Unifarco, Alfasigma, Shire, EG Stada Group; Marie Truyen: no conflicts of interest to disclose; Alessandro Armuzzi: consultant: AbbVie, Allergan, Amgen, Biogen, Bristol-Myers Squibb, Celgene, Celltrion, Eli-Lilly, Ferring, Gilead, Janssen, MSD, Mylan, Pfizer, Roche, Samsung Bioepis, Sandoz, and Takeda; lecture fees: AbbVie, Amgen, Biogen, Bristol-Myers Squibb, Chiesi, Ferring, Gilead, Janssen, MSD, Mitsubishi Tanabe, Nikkiso, Novartis, Pfizer, Roche, Samsung Bioepis, Sandoz, Takeda, and Tigenix; research grants: MSD, Takeda, and Pfizer; Davide G. Ribaldone: paid consultancys, lecture fees for the past two years: Janssen, Ferring, and Errekappa; Ariella Bar-Gil Shitrit: grants from Takeda, and Janssen; lecture fees and advisory consultancy: Takeda, Janssen, Neopharm, Abbvie, and Pfizer; Waqqas Afif: speaker advisory board member and/or clinical investigator for Abbvie and Arena Pharmaceuticals; Morine Fibelman: none; Pauliina Molander: lecture and consultancy fees, and advisory board member fees from Abbvie, Janssen-Cilag, MSD, Orion Pharma, Pfizer, Roche, Takeda, and Tillotts Pharma; Claire Liefferinckx: received consultancy fees from Takeda and speaker fees from Sandoz, Janssen, and Abbvie; Stephane Nancey: received consultancy fees from Abbvie, Novartis, Janssen, and Takeda, and speaker fees from Amgen, Mylan, Ferring, Sandoz, and Lilly; Mohamed Korani: nothing to disclose; Mariann Rutka: nothing to disclose; Borja Otero-Alvarin: nothing to disclose; Viktor Domislovic: nothing to disclose; Gerard Suris: nothing to disclose; Carl Eriksson: has served as a speaker, a consultant or an advisory board member for Takeda, Janssen Cilag, Pfizer, and Abbvie; Catarina Alves: nothing to disclose; Afroditi Mpitsouli: nothing to disclose; Caroline di Jiang: nothing to disclose; Katja Tepeš: nothing to disclose; Marina Coletta: nothing to disclose; Kalliopi Foteinogiannopoulou: no conflict of interest; Javier P. Gisbert: served as a speaker, a consultant, and an advisory member for or has received research funding from MSD, Abbvie, Pfizer, Kern Pharma, Biogen, Mylan, Takeda, Janssen, Roche, Sandoz, Celgene, Gilead, Ferring, Faes Farma, Shire Pharmaceuticals, Falk Pharma, Tillotts Pharma, Chiesi, Casen Fleet, Gebro Pharma, Otsuka Pharmaceutical, and Vifor Pharma; Hadar Amir-Barak: nothing to disclose; Mohamed Attuabi: none; Waqqas Afif: advisory board/consultant/investigator: Arena, Abbvie, Janssen, and Takeda; advisory board: Amgen, Ferring, Innomar, Merck, Novartis, and Pfizer; Carla Marinelli: none; Triana Lobaton: received financial support for research from Abbvie, Mylan, MSD, Mundipharma, Biogen, Janssen, Pfizer, and Takeda; speaker fees from Ferring, Janssen, and Takeda; and consultancy fees from Janssen; Daniela Pugliese: nothing to disclose; Nitsan Maharshak: received speaking and/or consulting fees from Abbvie, Pfizer, Takeda, Janssen, Ferring, Pfizer, and Neopharm and grant support from Takeda, Janssen, and Abbott; Anneline Cremer: received consultancy fees from Takeda and Janssen, and speaker fees from Pfizer and Abbvie; Jimmy K. Limdi: nothing to disclose; Tamás Molnár: nothing to disclose; Manuel Barreiro-de Acosta: served as a speaker, a consultant, and an advisory member for or has received research funding from MSD, Abbvie, Celltrion, Takeda, Janssen, Pfizer, Roche, Biogen, Adacyte, and Celgene; Zeljko Krznaric: received speaker fees from Abbvie, Takeda, MSD, Janssen, Oktal Pharma, Fresenius, Mylan, and Pfizer; Fernando Magro: served as speaker and received honoraria from: Abbvie, Amgen, Biogen, Falk, Ferring, Hospira, Janssen, Laboratório Vitoria, Merck Sharp & Dohme, Pfizer, Sandoz, Takeda, UCB, and Vifor; Konstantinos Karmiris received speaker fees from Abbvie, Aenorasis, Janssen, MSD, Pfizer, and Takeda and consultancy or advisory board fees from Abbvie, Amgen, Ferring, Galena, Genesis, Janssen, MSD, Pfizer, and Takeda; Tim Raine: received research/educational grants and/or speaker/consultation fees from Abbvie, Gilead, GSK, Janssen, MSD, Novartis, Pfizer, Sandoz, and Takeda; David Drohne: served as a speaker, a consultant and an advisory board member for MSD, Abbvie, Takeda, Pfizer, Janssen, Amgen, Biogen, and Krka; Ioannis Koutoulakis: received speaker fees from Abbvie, Aenorasis, Janssen, MSD, Pfizer and Takeda and consultancy or advisory board fees from Abbvie, Amgen, Ferring, Galena, Genesis, Janssen, MSD, Pfizer, and Takeda; Maria Chaparro: served as a speaker, a consultant and advisory member for or received research funding from MSD, Abbvie, Celltrion, Takeda, Janssen,
Pfizer, Ferring, Faes Farma, Shire Pharmaceuticals, Falk Pharma, Chiesi, Gebro Pharma, Roche, Otsuka Pharmaceuticals, and Tillotts Pharma; Henit Yanai: received a research grant from Pfizer and consultancy and speakers’ fees from Abbvie, Ferring, Janssen, Neopharm, Pfizer, Takeda, and Medtronic; Johan Burisch: personal fees from AbbVie, Samsung Bioepis, Janssen-Cilag, Celgene, MSD, Pfizer, Tillotts Pharma, and Takeda and unrestricted grant support from MSD, Takeda, Tillotts Pharma, Bristol Myers Squibb, and Novo Nordisk; Jakob Seidelin: research grants from Takeda and the Capital Region Denmark, national coordinator of studies from AbbVie, Arena Pharmaceuticals, Lilly, and Boehringer Ingelheim. None of these pertain to the research submitted here. Uri Kopylov received consultancy and speaker fees from Abbvie, Janssen, Takeda, MSD, and Medtronic, and research grants from Janssen, Takeda, and Medtronic.

References

1. Dreesen, E.; Van Stappen, T.; Ballet, V.; Peeters, M.; Compernolle, G.; Tops, S.; Van Steen, K.; Van Assche, G.; Ferrante, M.; Vermeire, S.; et al. Anti-infliximab antibody concentrations can guide treatment intensification in patients with Crohn’s disease who lose clinical response. *Aliment. Pharmacol. Ther.* 2017, 47, 346–355. [CrossRef]  
2. Kopylov, U.; Seidman, E. Predicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel disease. *Ther. Adv. Gastroenterol*. 2016, 9, 513–526. [CrossRef]  
3. Ben-Horin, S.; Chowers, Y. Tailoring anti-TNF therapy in IBD: Drug levels and disease activity. *Nat. Rev. Gastroenterol. Hepatol.* 2014, 11, 243–255. [CrossRef]  
4. Ben-Horin, S.; Kopylov, U. Optimizing anti-TNF treatments in inflammatory bowel disease. *Autoimmun. Rev.* 2014, 13, 24–30. [CrossRef]  
5. Liefwerinkx, C.; Verstockt, B.; Gils, A.; Noman, M.; Van Kemseke, C.; Macken, E.; De Vos, M.; Van Moerkercke, W.; Rahier, J.-F.; Bossuyt, P.; et al. Long-term Clinical Effectiveness of Ustekinumab in Patients with Crohn’s Disease Who Failed Biologic Therapies: A National Cohort Study. *J. Crohn’s Colitis* 2019, 13, 1401–1409. [CrossRef]  
6. Wils, P.; Bouhnik, Y.; Michetti, P.; Flourie, B.; Brixi, H.; Bourrier, A.; Allez, M.; Duclos, B.; Serrero, M.; Buisson, A.; et al. Long-term efficacy and safety of ustekinumab in 122 refractory Crohn’s disease patients: A multicentre experience. *Aliment. Pharmacol. Ther.* 2018, 47, 588–595. [CrossRef]  
7. Barré, A.; Colombel, J.-F.; Ungaro, R. Review article: Predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease. *Aliment. Pharmacol. Ther.* 2018, 47, 896–905. [CrossRef] [PubMed]  
8. Verstockt, B.; Dreesen, E.; Noman, M.; Outtlier, A.; Berghe, N.V.D.; Aarden, I.; Compernolle, G.; Van Assche, G.; Gils, A.; Vermeire, S.; et al. Ustekinumab Exposure-outcome Analysis in Crohn’s Disease Only in Part Explains Limited Endoscopic Remission Rates. *J. Crohn’s Colitis* 2019, 13, 864–872. [CrossRef] [PubMed]  
9. Khorrami, S.; Ginard, D.; Marín-Jiménez, I.; Chaparro, M.; Sierra, M.; Aguas, M.; Sicilia, B.; García-Sánchez, V.; Suarez, C.; Villoria, A.; et al. Ustekinumab for the Treatment of Refractory Crohn’s Disease. The Spanish Experience in a Large Multicentre Open-label Cohort. *Inflamm. Bowel Dis.* 2016, 22, 1662–1669. [CrossRef]  
10. Battat, R.; Kopylov, U.; Bessissow, T.; Bitton, A.; Cohen, A.; Jain, A.; Martel, M.; Seidman, E.; Afif, W. Association between Ustekinumab Trough Concentrations and Endoscopic Biomarker, and Endoscopic Outcomes in Patients with Crohn’s Disease. *Clin. Gastroenterol. Hepatol.* 2017, 15, 1427–1434.e2. [CrossRef] [PubMed]  
11. Kopylov, U.; Afif, W.; Cohen, A.; Bitton, A.; Wild, G.; Bessissow, T.; Wyse, J.; Al-Taweel, S.; Szilagyi, A.; Seidman, E. Subcutaneous ustekinumab for the treatment of anti-TNF resistant Crohn’s disease—The McGill experience. *J. Crohn’s Colitis* 2018, 14, 1516–1522. [CrossRef] [PubMed]  
12. Ollech, J.E.; Normatov, I.; Peleg, N.; Wang, J.; Patel, S.A.; Rai, V.; Yi, Y.; Singer, J.; Dalal, S.R.; Sakuraba, A.; et al. Effectiveness of Ustekinumab Dose Escalation in Patients with Crohn’s Disease. *Clin. Gastroenterol. Hepatol.* 2021, 19, 104–110. [CrossRef]  
13. Kopylov, U.; Hanzel, J.; Liefwerinkx, C.; De Marco, D.; Imperatore, N.; Plevris, N.; Baston-Rey, I.; Harris, R.J.; Truyen, M.; Domislovic, V.; et al. Effectiveness of ustekinumab dose escalation in Crohn’s disease patients with insufficient response to standard-dose subcutaneous maintenance therapy. *Aliment. Pharmacol. Ther.* 2020, 52, 135–142. [CrossRef] [PubMed]  
14. Engel, T.; Kopylov, U. Ustekinumab in Crohn’s disease: Evidence to date and place in therapy. *Ther. Adv. Chronic Dis.* 2016, 7, 208–214. [CrossRef] [PubMed]  
15. Engel, T.; Yung, D.E.; Ma, C.; Pariente, B.; Wils, P.; Eliakim, R.; Ungar, B.; Ben-Horin, S.; Kopylov, U. Effectiveness and safety of Ustekinumab in Crohn’s disease: systematic review and pooled analysis of real-world evidence. *Dig. Liver Dis.* 2019, 51, 1232–1240. [CrossRef] [PubMed]  
16. Phillips, F.M.; Verstockt, B.; Sebastian, S.; Ribaldone, D.G.; Vavricka, S.; Katsanos, K.; Slatterey, E.; De Suray, N.; Flores, C.; Fries, W.; et al. Inflammatory Cutaneous Lesions in Inflammatory Bowel Disease Treated with Vedolizumab or Ustekinumab: An ECCO CONFER Multicentre Case Series. *J. Crohn’s Colitis* 2020, 14. [CrossRef]  
17. Kopylov, U.; Verstockt, B.; Biedermann, L.; Sebastian, S.; Pugliese, D.; Sonnenberg, E.; Steinhagen, P.R.; Arebi, N.; Ron, Y.; Kucharz, T.; et al. Effectiveness and Safety of Vedolizumab in Anti-TNF-Naïve Patients with Inflammatory Bowel Disease—A Multicenter Retrospective European Study. *Inflamm. Bowel Dis.* 2018, 24, 2442–2451. [CrossRef] [PubMed]
18. Kopylov, U.; Ron, Y.; Avni-Biron, I.; Koslowsky, B.; Waterman, M.; Daher, S.; Ungar, B.; Yajnik, V.; Ananthakrishnan, A.; Korzenik, J. Predictors of Clinical Response to Vedolizumab for Induction of Remission in Inflammatory Bowel Disease—The Israeli Real-World Experience. *Inflamm. Bowel Dis.* 2017, 23, 404–408. [CrossRef]

19. Cohen, N.A.; Plevis, N.; Kopylov, U.; Grinman, A.; Ungar, B.; Yajnik, V.; Leibovitch, H.; Isakov, N.F.; Hirsch, A.; Ritter, E.; et al. Vedolizumab is effective and safe in elderly inflammatory bowel disease patients: A binational, multicenter, retrospective cohort study. *United Eur. Gastroenterol. J.* 2020, 8, 1076–1085. [CrossRef]

20. Zingone, F.; Barberio, B.; Compostella, F.; Girardin, G.; D’Incà, R.; Marinelli, C.; Marsilio, I.; Lorenzon, G.; Savarino, E.V. Good efficacy and safety of vedolizumab in Crohn’s disease and ulcerative colitis in a real-world scenario. *Ther. Adv. Gastroenterol.* 2020, 13. [CrossRef]

21. Schreiber, S.; Dignass, A.; Peyrin-Biroulet, L.; Hather, G.; DeMuth, D.; Mosli, M.; Curtis, R.; Khalid, J.M.; Loftus, E.V. Systematic review with meta-analysis: Real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease. *J. Gastroenterol.* 2018, 53, 1048–1064. [CrossRef] [PubMed]

22. Amiot, A.; Filippi, J.; Abitbol, V.; Cadiot, G.; Laharie, D.; Serrero, M.; Altwegg, R.; Bouhnik, Y.; Peyrin-Biroulet, L.; Gilletta, C.; et al. Effectiveness and safety of ustekinumab induction therapy for 103 patients with ulcerative colitis: A GETAID multicentre real-world cohort study. *Aliment. Pharmacol. Ther.* 2020, 51, 1039–1046. [CrossRef]

23. Allegretti, J.R.; Barnes, E.L.; Stevens, B.; Storm, M.; Ananthakrishnan, A.; Yajnik, V.; Korzenik, J. Predictors of Clinical Response and Remission at 1 Year Among a Multicenter Cohort of Patients with Inflammatory Bowel Disease Treated with Vedolizumab. *Dig. Dis. Sci.* 2017, 62, 1590–1596. [CrossRef]

24. De Vos, M.; Dhooghe, B.; Vermeire, S.; Louis, E.; Mana, F.; Elewaut, A.; Bossuyt, P.; Baert, F.; Reenaers, C.; Van Gossum, M.; et al. Efficacy of vedolizumab for induction of clinical response and remission in patients with moderate to severe inflammatory bowel disease who failed at least two TNF antagonists. *United Eur. Gastroenterol. J.* 2018, 6, 439–445. [CrossRef]

25. Christensen, B.; Colman, R.; Micic, D.; Gibson, P.R.; Goeppinger, S.R.; Yarur, A.; Weber, C.; Cohen, R.D.; Rubin, D.T. Vedolizumab as Induction and Maintenance for Inflammatory Bowel Disease: 12-month Effectiveness and Safety. *Inflamm. Bowel Dis.* 2018, 24, 849–860. [CrossRef]

26. Baumgart, D.C.; Bokemeyer, B.; Drabik, A.; Stallmach, A.; Schreiber, S. The Vedolizumab Germany Consortium Vedolizumab induction therapy for inflammatory bowel disease in clinical practice—A nationwide consecutive German cohort study. *Aliment. Pharmacol. Ther.* 2016, 43, 1090–1102. [CrossRef] [PubMed]

27. Biemans, V.B.C.; Van Der Woude, C.J.; Dijkstra, G.; Jong, A.E.V.D.M.-D.; Löwenberg, M.; De Boer, N.K.; Oldenburg, B.; Srivastava, N.; Jansen, J.M.; Bodelier, A.G.L.; et al. Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn’s disease patients with prior failure to anti-TNF treatment. *Aliment. Pharmacol. Ther.* 2020, 52, 123–134. [CrossRef]

28. Alric, H.; Amiot, A.; Kirchgasser, J.; Tréton, X.; Allez, M.; Bouhnik, Y.; Beaugerie, L.; Carbonnel, F.; Meyer, A. The effectiveness of either ustekinumab or vedolizumab in 239 patients with Crohn’s disease refractory to anti-tumour necrosis factor. *Aliment. Pharmacol. Ther.* 2020, 51, 948–957. [CrossRef] [PubMed]

29. Taxonera, C.; Rodriguez, C.; Bertolotti, F.; Menché, L.; Arribas, J.; Sierra, M.; Arias, L.; Martinez-Montiel, P.; Juan, A.; Iglesias, E.; et al. Clinical Outcomes of Golimumab as First, Second or Third Anti-TNF Agent in Patients with Moderate-to-Severe Ulcerative Colitis. *Inflamm. Bowel Dis.* 2017, 23, 1394–1402. [CrossRef]

30. Kassouri, L.; Amiot, A.; Kirchgasser, J.; Tréton, X.; Allez, M.; Bouhnik, Y.; Beaugerie, L.; Carbonnel, F.; Meyer, A. The outcome of Crohn’s disease patients refractory to anti-TNF and either vedolizumab or ustekinumab. *Dig. Liver Dis.* 2020, 52, 1148–1155. [CrossRef]

31. Silva, P.S.A.; Nguyen, D.D.; Sauk, J.; Korzenik, J.; Yajnik, V.; Ananthakrishnan, A.N. Long-term outcome of a third anti-TNF monoclonal antibody after the failure of two prior anti-TNFs in inflammatory bowel disease. *Aliment. Pharmacol. Ther.* 2012, 36, 459–466. [CrossRef]

32. Gisbert, J.P.; Chaparro, M. Use of a third anti-TNF after failure of two previous anti-TNFs in patients with inflammatory bowel disease: Is it worth it? *Scand. J. Gastroenterol.* 2015, 50, 379–386. [CrossRef]

33. Iborra, M.; Spanish Working Group on Crohn’s Disease and Ulcerative Colitis (GETECCU); Pérez-Gisbert, J.; Bosca-Watts, M.M.; López-García, A.; García-Sánchez, V.; López-Sanromán, A.; Hinojosa, E.; Márquez, L.; López, S.G.; et al. Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: Comparison between anti-tumour necrosis factor-naive and non-naïve patients. *J. Gastroenterol.* 2016, 52, 788–799. [CrossRef]

34. Verstockt, B.; Mertens, E.; Dreessen, E.; Outtier, A.; Noman, M.; Tops, S.; Schops, G.; Van Assche, G.; Vermeire, S.; Gils, A.; et al. Influence of Drug Exposure on Vedolizumab-Induced Endoscopic Remission in Anti-Tumour Necrosis Factor [TNF] Naïve and Anti-TNF Exposed IBD Patients. *J. Crohn’s Colitis* 2019, 14, 332–341. [CrossRef]

35. Orlandini, B.; Dragoni, G.; Variola, A.; Massella, A.; Bagnoli, S.; Campi, R.; Rogai, F. Clinical efficacy and safety of golimumab in biologically experienced and naive patients with active ulcerative colitis: A real-life experience from two Italian IBD centers. *J. Dig. Dis.* 2018, 19, 468–474. [CrossRef] [PubMed]

36. Feagan, B.G.; Lasch, K.; Lissooms, T.; Cao, C.; Wojtowicz, A.M.; Khalid, J.M.; Colombel, J.-F. Rapid Response to Vedolizumab Therapy in Biologic-Naive Patients with Inflammatory Bowel Diseases. *Clin. Gastroenterol. Hepatol.* 2019, 17, 130–138.e7. [CrossRef] [PubMed]
37. Sands, B.E.; Sandborn, W.J.; Van Assche, G.; Lukas, M.; Xu, J.; James, A.; Abhyankar, B.; Lasch, K. Vedolizumab as Induction and Maintenance Therapy for Crohn’s Disease in Patients Naïve to or Who Have Failed Tumor Necrosis Factor Antagonist Therapy. *Inflamm. Bowel Dis.* 2017, 23, 97–106. [CrossRef]

38. Stallmach, A.; Langbein, C.; Atreya, R.; Bruns, T.; Dignass, A.; Ende, K.; Hampe, J.; Hartmann, F.; Neurath, M.F.; Maul, J.; et al. Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease—A prospective multicenter observational study. *Aliment. Pharmacol. Ther.* 2016, 44, 1199–1212. [CrossRef]

39. Bohm, M.; Xu, R.; Zhang, Y.; Varma, S.; Fischer, M.; Kochhar, G.; Boland, B.; Singh, S.; Hirten, R.; Ungaro, R.; et al. Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn’s disease. *Aliment. Pharmacol. Ther.* 2020, 52, 669–681. [CrossRef]

40. Dulai, P.S.; Singh, S.; Jiang, X.; Peerani, F.; Narula, N.; Chaudrey, K.; Whitehead, D.; Hudesman, D.; Lukin, D.; Swaminathan, A.; et al. The Real-World Effectiveness and Safety of Vedolizumab for Moderate–Severe Crohn’s Disease: Results from the US VICTORY Consortium. *Am. J. Gastroenterol.* 2016, 111, 1147–1155. [CrossRef] [PubMed]

41. Alric, H.; Amiot, A.; Carbonnel, F.; Meyer, A. Letter: Choosing between ustekinumab and vedolizumab in anti-TNF refractory Crohn’s disease—the devil is in the detail. Authors’ reply. *Aliment. Pharmacol. Ther.* 2020, 52, 563–564. [CrossRef] [PubMed]

42. Iborra, M.; Beltrán, B.; Fernández-Clotet, A.; Iglesias-Flores, E.; Navarro, P.; Rivero, M.; Gutiérrez, A.; Sierra-Ausin, M.; Mesonero, F.; Ferreiro-Iglesias, R.; et al. Real-world long-term effectiveness of ustekinumab in Crohn’s disease: Results from the ENEIDA registry. *Aliment. Pharmacol. Ther.* 2020. [CrossRef] [PubMed]

43. Engel, T.; Ungar, B.; Yung, D.E.; Ben-Horin, S.; Eliakim, R.; Kopylov, U. Vedolizumab in IBD—Lessons from Real-world Experience; A Systematic Review and Pooled Analysis. *J. Crohn’s Colitis* 2017, 12, 245–257. [CrossRef] [PubMed]

44. Roblin, X.; Williet, N.; Boschetti, G.; Phelip, J.-M.; Del Tedesco, E.; Berger, A.-E.; Vedrines, P.; Duru, G.; Peyrin-Biroulet, L.; et al. Addition of azathioprine to the switch of anti-TNF in patients with inflammatory bowel diseases: A Meta-Analysis. *Clin. Gastroenterol. Hepatol.* 2021, 19, 668–679.e8. [CrossRef] [PubMed]

45. Narula, N.; Aruljothy, A.; Wong, E.C.L.; Homenauth, R.; Alshahrani, A.; Marshall, J.K.; Reinsch, W. The impact of ustekinumab on extraintestinal manifestations of Crohn’s disease: A post hoc analysis of the UNITI studies. *United Eur. Gastroenterol. J.* 2021. [CrossRef] [PubMed]